Adial Pharmaceuticals, Inc. Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation
Adial Pharmaceuticals, Inc. (ADIL) had Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation of $294.29 thousand as of 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Liability Assumed, Liability
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation · last filed 2023-03-30
- 2022-12-31: Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation $294.29K.
| Period end | Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation |
|---|---|
| 2022-12-31 | $294.29K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |